Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
AUNA Q3 2026: +10% FXN Revenue Growth with Margin Pressure in Focus

AUNA Q3 2026: +10% FXN Revenue Growth with Margin Pressure in Focus

Key Takeaways

  • Revenue rose 10% year over year on a foreign-exchange-neutral (FXN, or currency-adjusted) basis, reaching S/1,325 million.
  • Adjusted EBITDA fell 5% on an FXN basis to S/231 million, with an adjusted EBITDA margin of 17.5%.
  • Mexico returned to year-over-year segment adjusted EBITDA growth (up 5%), while Colombia declined 30% amid an adverse oncology contract and regulatory price caps.
  • Net income came in at S/24 million, down from S/53 million a year earlier, partly reflecting a non-cash foreign-exchange gain that did not recur.
  • Cash generation stayed strong, with year-to-date operating cash flow up 62% and free cash flow up 95%.
  • Management reaffirmed full-year 2026 revenue guidance but now expects adjusted EBITDA to be broadly stable or slightly down.

Why This Quarter Matters

Auna, a leading Latin American healthcare platform with operations in Mexico, Peru, and Colombia, combines hospitals, oncology services, and health plans. The third-quarter 2026 results provide a useful test of whether the company can maintain commercial momentum while addressing profitability, especially in Mexico and Colombia. Recent periods have featured solid revenue gains alongside uneven margin trends, so it is worth monitoring whether cost pressures and contract issues prove temporary. With management set to host a 2026 Investor Day and having updated its outlook, this report gives a clearer picture of earnings quality, debt reduction, and cash generation across the three main markets.

The Numbers at a Glance

Auna posted third-quarter 2026 revenue of S/1,325 million, up 10% year over year on an FXN basis and 19% as reported. Local-currency growth reached 16% in Mexico, 6% in Peru, and 12% in Colombia, supported by higher surgery and oncology volumes, complex procedures, and added hospital capacity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Adjusted EBITDA declined 5% year over year on an FXN basis to S/231 million, holding flat as reported, with a margin of 17.5%. Segment adjusted EBITDA grew 5% in Mexico—its first year-over-year increase of 2026—but fell 6% in Peru and 30% in Colombia. Colombia’s drop reflected higher medical costs under a specific oncology risk-sharing contract that has since been terminated, plus regulatory price caps on certain high-cost oncology medications. Peru felt the impact of penalties linked to prior-year receivables reconciliations and a higher medical loss ratio.

Net income totaled S/24 million, down from S/53 million a year earlier, mainly because a S/40 million non-cash foreign-exchange gain from the prior period did not repeat. On a per-share basis, net income was S/0.27, while adjusted net income was S/35 million, or S/0.41 per share. Operating metrics remained positive: surgeries rose 12%, hospital days increased 6%, and chemotherapy and radiotherapy sessions grew 7%. Management kept full-year 2026 revenue guidance at 10%–14% FXN growth but now expects adjusted EBITDA to be broadly stable or slightly down year over year.

Market Reaction

Investor reaction to Auna’s third-quarter 2026 report stayed measured. Top-line growth held steady and cash flow generation stood out, yet the drop in adjusted EBITDA and the steep decline in Colombia’s profitability drew attention. The decision to end the problematic oncology risk-sharing contract and the engagement of legal counsel to explore recovery options show management is addressing the issues, though near-term earnings pressure weighed on sentiment. Market data showed the stock trading lower after the release, with investors focusing more on margin durability than revenue momentum. The reaffirmed revenue outlook alongside softer adjusted EBITDA expectations framed the report as solid commercial expansion offset by ongoing profitability challenges.

What Comes Next

Looking forward, Auna’s progress will hinge on restoring profitability in Colombia while keeping Mexico’s recovery on track. Ending the oncology risk-sharing contract removes one source of volatility, but it will be important to see whether legal recovery efforts produce results and how regulatory price caps develop. In Peru, attention stays on receivables reconciliation and the health-plan mix that has lifted the medical loss ratio.

Cash flow and leverage metrics will matter just as much. Year-to-date free cash flow growth and a leverage ratio moving toward 3.5x support the medium-term target of moving below 3.0x. Further debt reduction would strengthen the balance sheet and create room for growth investments.

Capital deployment and expansion projects also deserve watching, including the Centro Ambulatorio Trecca in Lima, a capital-light public-private partnership that management expects to provide longer-term revenue visibility. With full-year 2026 revenue guidance confirmed but adjusted EBITDA now projected to be broadly stable or slightly down, the central question is whether margin pressures ease soon enough to rebuild confidence in earnings growth.

Integrating AI Tools into My Research

When reviewing earnings like these, I often turn to Tickeron’s AI Screener to quickly filter peers and spot patterns in healthcare stocks. The tool helps me cross-check technical signals, fundamentals, and recent performance so I can place the quarter in better context without spending hours on manual screens. It has become a regular part of how I build and refine watchlists around earnings season.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AUNA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AUNA's RSI Indicator climbs out of oversold territory

The RSI Indicator for AUNA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 16 of the 18 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 28 of 36 cases where AUNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on AUNA as a result. In 44 of 57 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for AUNA just turned positive on November 17, 2026. Looking at past instances where AUNA's MACD turned positive, the stock continued to rise in 17 of 22 cases over the following month. The odds of a continued upward trend are 77%.

Following a +3.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUNA advanced for three days, in 75 of 121 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

AUNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

AUNA moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AUNA crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

The 50-day moving average for AUNA moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. AUNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.186) is normal, around the industry mean (204.532). P/E Ratio (21.273) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.289) is also within normal values, averaging (2.688).

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -10%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 3%. AUNA experienced the highest price growth at 4%, while BMGL experienced the biggest fall at -83%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -25%. For the same stocks of the Industry, the average monthly volume growth was 52% and the average quarterly volume growth was -2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 47
Price Growth Rating: 54
SMR Rating: 66
Profit Risk Rating: 82
Seasonality Score: -5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Industry
N/A
Address
No. 6, rue Jean Monnet
Phone
N/A
Employees
15254
Web
https://www.auna.org
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
AUNA Q3 2026: +10% FXN Revenue Growth with Margin Pressure in Focus